Singapore, Feb. 26 -- US-based startup HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by China-based Harbour BioMed (HKEX: 02142), has announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.

Under the agreement, the partner gains exclusive global rights, excludingGreater China(mainlandChina,Taiwan,Hong Kong, andMacau), to develop and commercialise HAT001 (designated as HBM9013 by Harbour BioMed), a potent and selective anti-CRH-neutralising antibody.

In return, HBMAT is eligible to receive up to $395million, including upfront, development, regulatory and commercial milestone pay...